- Chemotherapy
- Radiotherapy
- Stem Cell Transplantation
- Others
Relapsed and refracted multiple myeloma market is poised to grow at a significant CAGR owing to increase in the prevalence of multiple myeloma. According to World Cancer Research Fund International 2012, approximately 114,000 multiple myeloma cases observed around the world. According to Novartis data 2015, approximately 75,000 people are living with relapsed and refractory multiple myeloma around the globe. Moreover, strong product pipeline for relapsed and refractory multiple myeloma treatment expected to boost the market. For instance, in April 2017, Genmab A/S announced that Janssen Research and Development LLC collaborated with European Myeloma Network (EMN) to start phase III study of daratumumab in combination with dexamethasone and pomalidomide in relapsed and refractory multiple myeloma. In addition, FDA approval for various drugs might upsurge the revenue of market. For instance, in January 2016, Amgen received FDA approval for supplemental New Drug Application (sNDA) of Kyprolis (carfilzomib) injection in combination with lenalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma. Relapsed multiple myeloma occurs when the multiple myeloma disease or its signs and symptoms return after a period of improvement. Relapsed and Refractory Multiple Myeloma Treatment Market occurs when the disease in unresponsive to a primary therapy or it becomes unresponsive over time. Multiple myeloma or plasma cell myeloma, is a cancer of plasma cells, a type of WBC normally responsible for the production of antibodies. At initial stage, there are no symptoms noticed with multiple myeloma, however, in advanced stage bleeding, bone pain, anemia, and frequent infections may occur. Risk factors for multiple myeloma are high consumption of alcohol and obesity. It may causes due to abnormal production of antibodies may cause renal problems and increase in the thickness of blood. The disease can be considered as treatable, but incurable. It can be treated with radiotherapy, chemotherapy, and stem cell transplantation among others.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Increase in the prevalence of relapsed and refractory multiple myeloma, rise in R&D for the innovation of newer drugs, funding for the R&D activities from public and private sectors, and promising pipeline products are anticipated to fuel the relapsed and refractory multiple myeloma treatment market over the forecast years. Moreover, increase in awareness about relapsed and refractory myeloma treatment, government initiations for prevention of cancer, and launching of newer products into the market are bolster the relapsed and refractory multiple myeloma treatment market. However, stringent regulatory policies for product approval, high cost of R&D activities, and adverse effects associated with chemotherapy and radiotherapy may hinder the growth of the market over the forecast timeframe.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
[urltag url='request-table-of-content']